Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing.

Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing.

Malignant gliomas are aggressive brain tumours with very poor prognosis. The majority of glioma cells are differentiated (glioma-differentiated cells: GDCs), whereas the smaller population (glioma-initiating cells, GICs) is undifferentiated and resistant to conventional therapies. Therefore, to bett...

Full description

Bibliographic Details
Main Authors: Cristina Riccadonna, Céline Yacoub Maroun, Romain Vuillefroy de Silly, Margaux Boehler, Marta Calvo Tardón, Simone Jueliger, Pietro Taverna, Leticia Barba, Eliana Marinari, Serena Pellegatta, Esen Yonca Bassoy, Denis Martinvalet, Pierre-Yves Dietrich, Paul R Walker
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5007044?pdf=render

Internet

http://europepmc.org/articles/PMC5007044?pdf=render

Similar Items